Imaging in the age of molecular medicine: Monitoring of anti-angiogenic treatments

Current Pharmaceutical Biotechnology

Volumn 13, Issue 4, 2012, Pages 595-608

  Lederle, W ^a   Palmowski, M ^a   Kiessling, F ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Angiogenesis; CT; Imaging; MRI; Nuclear imaging; Optical imaging; Ultrasound

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANGIOGENESIS INHIBITOR; CARBON MONOXIDE; MATRIX METALLOPROTEINASE; OXYGEN 15; TRACER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANGIOGENESIS; BLOOD VOLUME; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR ANGIOGENESIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84857731623     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799436348     Document Type: Review

References (97)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
2. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3, 401-410.
3. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2002, 2, 795-803.
4. Baluk, P.; Hashizume, H.; McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev., 2005, 15, 102-111.
5. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156, 1363-1380.
6. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2002, 2, 727-739.
7. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 2007, 6, 273-286.
8. Rudin, M.; Weissleder, R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov., 2003, 2, 123-131.
9. Laking, G.R.; Price, P.M. Positron emission tomographic imaging of angiogenesis and vascular function. Br. J. Radiol., 2003, 76 (Spec No 1), S50-S59.
10. Delbeke, D.; Schoder, H.; Martin, W.H.; Wahl, R.L. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin. Nucl. Med., 2009, 39, 308-340.
11. Weber, W.A. Monitoring tumor response to therapy with 18F-FLT PET. J. Nucl. Med., 2010, 51, 841-844.
12. Niu, G.; Chen, X. PET Imaging of Angiogenesis. PET. Clin., 2009, 4, 17-38.
13. Haubner, R.; Wester, H.J.; Reuning, U.; Senekowitsch-Schmidtke, R.; Diefenbach, B.; Kessler, H.; Stocklin, G.; Schwaiger, M. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med., 1999, 40, 1061-1071.
14. Haubner, R.; Weber, W.A.; Beer, A.J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.F.; Goebel, M.; Hein, R.; Wester, H.J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS. Med., 2005, 2, e70.
15. Beer, A.J.; Haubner, R.; Goebel, M.; Luderschmidt, S.; Spilker, M.E.; Wester, H.J.; Weber, W.A.; Schwaiger, M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18Fgalacto-RGD in cancer patients. J Nucl. Med., 2005, 46, 1333-1341.
16. Beer, A.J.; Haubner, R.; Sarbia, M.; Goebel, M.; Luderschmidt, S.; Grosu, A.L.; Schnell, O.; Niemeyer, M.; Kessler, H.; Wester, H.J.; Weber, W.A.; Schwaiger, M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res., 2006, 12, 3942-3949.
17. Beer, A.J.; Grosu, A.L.; Carlsen, J.; Kolk, A.; Sarbia, M.; Stangier, I.; Watzlowik, P.; Wester, H.J.; Haubner, R.; Schwaiger, M. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res., 2007, 13, 6610-6616.
18. Bach-Gansmo, T.; Danielsson, R.; Saracco, A.; Wilczek, B.; Bogsrud, T.V.; Fangberget, A.; Tangerud, A.; Tobin, D. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med., 2006, 47, 1434-1439.
19. van Hagen, P.M.; Breeman, W.A.; Bernard, H.F.; Schaar, M.; Mooij, C.M.; Srinivasan, A.; Schmidt, M.A.; Krenning, E.P.; de, J.M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer, 2000, 90, 186-198.
20. Cai, W.; Wu, Y.; Chen, K.; Cao, Q.; Tice, D.A.; Chen, X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res., 2006, 66, 9673-9681.
21. Jayson, G.C.; Zweit, J.; Jackson, A.; Mulatero, C.; Julyan, P.; Ranson, M.; Broughton, L.; Wagstaff, J.; Hakannson, L.; Groenewegen, G.; Bailey, J.; Smith, N.; Hastings, D.; Lawrance, J.; Haroon, H.; Ward, T.; McGown, A.T.; Tang, M.; Levitt, D.; Marreaud, S.; Lehmann, F.F.; Herold, M.; Zwierzina, H. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst., 2002, 94, 1484-1493.
22. Scheer, M.G.; Stollman, T.H.; Boerman, O.C.; Verrijp, K.; Sweep, F.C.; Leenders, W.P.; Ruers, T.J.; Oyen, W.J. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur. J. Cancer, 2008, 44, 1835-1840.
23. Nagengast, W.B.; de Vries, E.G.; Hospers, G.A.; Mulder, N.H.; de, J. Jr.; Hollema, H.; Brouwers, A.H.; van Dongen, G.A.; Perk, L.R.; Lub-de Hooge, M.N. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med., 2007, 48, 1313-1319.
24. Cai, W.; Chen, K.; Mohamedali, K.A.; Cao, Q.; Gambhir, S.S.; Rosenblum, M.G.; Chen, X. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med., 2006, 47, 2048-2056.
25. Sprague, J.E.; Li, W.P.; Liang, K.; Achilefu, S.; Anderson, C.J. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl. Med. Biol., 2006, 33, 227-237.
26. Barrett, T.; Brechbiel, M.; Bernardo, M.; Choyke, P.L. MRI of tumor angiogenesis. J. Magn. Reson. Imaging, 2007, 26, 235-249.
27. Boss, A.; Martirosian, P.; Schraml, C.; Clasen, S.; Fenchel, M.; Anastasiadis, A.; Claussen, C.D.; Pereira, P.L.; Schick, F. Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas. Eur. Radiol., 2006, 16, 1226-1236.
28. Gilead, A.; Meir, G.; Neeman, M. The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. Int. J. Cancer, 2004, 108, 524-531.
29. Matsumoto, S.; Yasui, H.; Batra, S.; Kinoshita, Y.; Bernardo, M.; Munasinghe, J.P.; Utsumi, H.; Choudhuri, R.; Devasahayam, N.; Subramanian, S.; Mitchell, J.B.; Krishna, M.C. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc. Natl. Acad. Sci. USA, 2009, 106, 17898-17903.
30. Persigehl, T.; Bieker, R.; Matuszewski, L.; Wall, A.; Kessler, T.; Kooijman, H.; Meier, N.; Ebert, W.; Berdel, W.E.; Heindel, W.; Mesters, R.M.; Bremer, C. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology, 2007, 244, 449-456.
31. Persigehl, T.; Matuszewski, L.; Kessler, T.; Wall, A.; Meier, N.; Ebert, W.; Berdel, W.E.; Heindel, W.; Mesters, R.; Bremer, C. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest. Radiol., 2007, 42, 791-796.
32. Tofts, P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging, 1997, 7, 91-101.
33. Brix, G.; Bahner, M.L.; Hoffmann, U.; Horvath, A.; Schreiber, W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT--initial experience. Radiology, 1999, 210, 269-276.
34. Padhani, A.R.; Hayes, C.; Assersohn, L.; Powles, T.; Makris, A.; Suckling, J.; Leach, M.O.; Husband, J.E. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology, 2006, 239, 361-374.
35. Kiessling, F.; Jugold, M.; Woenne, E.C.; Brix, G. Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur. Radiol., 2007, 17, 2136-2148.
36. Bauerle, T.; Bartling, S.; Berger, M.; Schmitt-Graff, A.; Hilbig, H.; Kauczor, H.U.; Delorme, S.; Kiessling, F. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur. J. Radiol., 2010, 73, 280-287.
37. Su, M.Y.; Muhler, A.; Lao, X.; Nalcioglu, O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn. Reson. Med., 1998, 39, 259-269.
38. Verhoye, M.; van der Sanden, B.P.; Rijken, P.F.; Peters, H.P.; Van der Kogel, A.J.; Pee, G.; Vanhoutte, G.; Heerschap, A.; Van der, L.A. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. Magn. Reson. Med., 2002, 47, 305-313.
39. Kassner, A.; Thornhill, R.E.; Liu, F.; Winter, P.M.; Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model. Contrast. Media Mol. Imaging, 2010, 5, 155-161.
40. Wu, X.; Jeong, E.K.; Emerson, L.; Hoffman, J.; Parker, D.L.; Lu, Z.R. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol. Pharm., 2010, 7, 41-48.
41. Marzola, P.; Degrassi, A.; Calderan, L.; Farace, P.; Crescimanno, C.; Nicolato, E.; Giusti, A.; Pesenti, E.; Terron, A.; Sbarbati, A.; Abrams, T.; Murray, L.; Osculati, F. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin. Cancer Res., 2004, 10, 739-750.
42. Lee, L.; Sharma, S.; Morgan, B.; Allegrini, P.; Schnell, C.; Brueggen, J.; Cozens, R.; Horsfield, M.; Guenther, C.; Steward, W.P.; Drevs, J.; Lebwohl, D.; Wood, J.; McSheehy, P.M. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol., 2006, 57, 761-771.
43. de Lussanet, Q.G.; Beets-Tan, R.G.; Backes, W.H.; van der Schaft, D.W.; van Engelshoven, J.M.; Mayo, K.H.; Griffioen, A.W. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. Eur. J. Cancer, 2004, 40, 1262-1268.
44. Kiessling, F.; Farhan, N.; Lichy, M.P.; Vosseler, S.; Heilmann, M.; Krix, M.; Bohlen, P.; Miller, D.W.; Mueller, M.M.; Semmler, W.; Fusenig, N.E.; Delorme, S. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia., 2004, 6, 213-223.
45. Morgan, B.; Thomas, A.L.; Drevs, J.; Hennig, J.; Buchert, M.; Jivan, A.; Horsfield, M.A.; Mross, K.; Ball, H.A.; Lee, L.; Mietlowski, W.; Fuxuis, S.; Unger, C.; O'Byrne, K.; Henry, A.; Cherryman, G.R.; Laurent, D.; Dugan, M.; Marme, D.; Steward, W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol., 2003, 21, 3955-3964.
46. Liu, G.; Rugo, H.S.; Wilding, G.; McShane, T.M.; Evelhoch, J.L.; Ng, C.; Jackson, E.; Kelcz, F.; Yeh, B.M.; Lee, F.T., Jr.; Charnsangavej, C.; Park, J.W.; Ashton, E.A.; Steinfeldt, H.M.; Pithavala, Y.K.; Reich, S.D.; Herbst, R.S. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol., 2005, 23, 5464-5473.
47. Xiong, H.Q.; Herbst, R.; Faria, S.C.; Scholz, C.; Davis, D.; Jackson, E.F.; Madden, T.; McConkey, D.; Hicks, M.; Hess, K.; Charnsangavej, C.A.; Abbruzzese, J.L. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs, 2004, 22, 459-466.
48. Ning, S.; Laird, D.; Cherrington, J.M.; Knox, S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res., 2002, 157, 45-51.
49. Kiessling, F.; Huppert, J.; Zhang, C.; Jayapaul, J.; Zwick, S.; Woenne, E.C.; Mueller, M.M.; Zentgraf, H.; Eisenhut, M.; Addadi, Y.; Neeman, M.; Semmler, W. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology, 2009, 253, 462-469.
50. Mulder, W.J.; Strijkers, G.J.; van Tilborg, G.A.; Griffioen, A.W.; Nicolay, K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed., 2006, 19, 142-164.
51. Mulder, W.J.; Strijkers, G.J.; Habets, J.W.; Bleeker, E.J.; van der Schaft, D.W.; Storm, G.; Koning, G.A.; Griffioen, A.W.; Nicolay, K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J., 2005, 19, 2008-2010.
52. Mulder, W.J.; van der Schaft, D.W.; Hautvast, P.A.; Strijkers, G.J.; Koning, G.A.; Storm, G.; Mayo, K.H.; Griffioen, A.W.; Nicolay, K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J., 2007, 21, 378-383.
53. Oostendorp, M.; Douma, K.; Hackeng, T.M.; Dirksen, A.; Post, M.J.; van Zandvoort, M.A.; Backes, W.H. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGRlabeled paramagnetic quantum dots. Cancer Res., 2008, 68, 7676-7683.
54. Judenhofer, M.S.; Wehrl, H.F.; Newport, D.F.; Catana, C.; Siegel, S.B.; Becker, M.; Thielscher, A.; Kneilling, M.; Lichy, M.P.; Eichner, M.; Klingel, K.; Reischl, G.; Widmaier, S.; Rocken, M.; Nutt, R.E.; Machulla, H.J.; Uludag, K.; Cherry, S.R.; Claussen, C.D.; Pichler, B.J. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med., 2008, 14, 459-465.
55. Miles, K.A.; Hayball, M.P.; Dixon, A.K. Functional images of hepatic perfusion obtained with dynamic CT. Radiology, 1993, 188, 405-411.
56. Goh, V.; Halligan, S.; Daley, F.; Wellsted, D.M.; Guenther, T.; Bartram, C.I. Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis? Radiology, 2008, 249, 510-517.
57. d'Assignies, G.; Couvelard, A.; Bahrami, S.; Vullierme, M.P.; Hammel, P.; Hentic, O.; Sauvanet, A.; Bedossa, P.; Ruszniewski, P.; Vilgrain, V. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology, 2009, 250, 407-416.
58. Bauerle, T.; Semmler, W. Imaging response to systemic therapy for bone metastases. Eur. Radiol., 2009, 19, 2495-2507.
59. O'Connor, J.P.; Carano, R.A.; Clamp, A.R.; Ross, J.; Ho, C.C.; Jackson, A.; Parker, G.J.; Rose, C.J.; Peale, F.V.; Friesenhahn, M.; Mitchell, C.L.; Watson, Y.; Roberts, C.; Hope, L.; Cheung, S.; Reslan, H.B.; Go, M.A.; Pacheco, G.J.; Wu, X.; Cao, T.C.; Ross, S.; Buonaccorsi, G.A.; Davies, K.; Hasan, J.; Thornton, P.; del, P.O.; Ferrara, N.; van, B.N.; Jayson, G.C. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res., 2009, 15, 6674-6682.
60. Ong, L.C.; Song, I.C.; Jin, Y.; Kee, I.H.; Siew, E.; Yu, S.; Thng, C.H.; Huynh, H.; Chow, P.K. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol. Imaging Biol., 2009, 11, 334-342.
61. Groves, A.M.; Shastry, M.; Rodriguez-Justo, M.; Malhotra, A.; Endozo, R.; Davidson, T.; Kelleher, T.; Miles, K.A.; Ell, P.J.; Keshtgar, M.R. (18)F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(1),46-52
62. Kiessling, F.; Huppert, J.; Palmowski, M. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr. Med. Chem., 2009, 16, 627-642.
63. Jugold, M.; Palmowski, M.; Huppert, J.; Woenne, E.C.; Mueller, M.M.; Semmler, W.; Kiessling, F. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice. Eur. Radiol., 2008, 18, 753-758.
64. Emoto, M.; Tachibana, K.; Iwasaki, H.; Kawarabayashi, T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci., 2007, 98, 929-935.
65. Palmowski, M.; Lederle, W.; Gaetjens, J.; Socher, M.; Hauff, P.; Bzyl, J.; Semmler, W.; Gunther, R.W.; Kiessling, F. Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. Eur. J. Radiol., 2010, 75(1),e149-153.
66. Palmowski, M.; Huppert, J.; Hauff, P.; Reinhardt, M.; Schreiner, K.; Socher, M.A.; Hallscheidt, P.; Kauffmann, G.W.; Semmler, W.; Kiessling, F. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res., 2008, 68, 7042-7049.
67. Cheung, A.M.; Brown, A.S.; Cucevic, V.; Roy, M.; Needles, A.; Yang, V.; Hicklin, D.J.; Kerbel, R.S.; Foster, F.S. Detecting vascular changes in tumour xenografts using micro-ultrasound and microct following treatment with VEGFR-2 blocking antibodies. Ultrasound Med. Biol., 2007, 33, 1259-1268.
68. Lassau, N.; Lamuraglia, M.; Vanel, D.; Le, C.A.; Chami, L.; Jaziri, S.; Terrier, P.; Roche, A.; Leclere, J.; Bonvalot, S. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann. Oncol., 2005, 16, 1054-1060.
69. Lamuraglia, M.; Lassau, N.; Garbay, J.R.; Mathieu, M.C.; Rouzier, R.; Jaziri, S.; Roche, A.; Leclere, J. Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: a prospective phase II study. Eur. J. Radiol., 2005, 56, 376-381.
70. Lamuraglia, M.; Escudier, B.; Chami, L.; Schwartz, B.; Leclere, J.; Roche, A.; Lassau, N. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur. J. Cancer, 2006, 42, 2472-2479.
71. Lassau, N.; Koscielny, S.; Albiges, L.; Chami, L.; Benatsou, B.; Chebil, M.; Roche, A.; Escudier, B.J. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin. Cancer Res., 2010, 16, 1216-1225.
72. Wei, K.; Jayaweera, A.R.; Firoozan, S.; Linka, A.; Skyba, D.M.; Kaul, S. Quantification of myocardial blood flow with ultrasoundinduced destruction of microbubbles administered as a constant venous infusion. Circulation, 1998, 97, 473-483.
73. Guibal, A.; Taillade, L.; Mule, S.; Comperat, E.; Badachi, Y.; Golmard, J.L.; Le Guillou-Buffello, D.; Rixe, O.; Bridal, S.L.; Lucidarme, O. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology, 2010, 254, 420-429.
74. Lindner, J.R. Microbubbles in medical imaging: current applications and future directions. Nat. Rev. Drug Discov., 2004, 3, 527-532.
75. Ellegala, D.B.; Leong-Poi, H.; Carpenter, J.E.; Klibanov, A.L.; Kaul, S.; Shaffrey, M.E.; Sklenar, J.; Lindner, J.R. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation, 2003, 108, 336-341.
76. Willmann, J.K.; Cheng, Z.; Davis, C.; Lutz, A.M.; Schipper, M.L.; Nielsen, C.H.; Gambhir, S.S. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology, 2008, 249, 212-219.
77. Klibanov, A.L. Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. Bioconjug. Chem., 2005, 16, 9-17.
78. Lindner, J.R.; Song, J.; Christiansen, J.; Klibanov, A.L.; Xu, F.; Ley, K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation, 2001, 104, 2107-2112.
79. Reinhardt, M.; Hauff, P.; Briel, A.; Uhlendorf, V.; Linker, R.A.; Maurer, M.; Schirner, M. Sensitive particle acoustic quantification (SPAQ): a new ultrasound-based approach for the quantification of ultrasound contrast media in high concentrations. Invest. Radiol., 2005, 40, 2-7.
80. Willmann, J.K.; Paulmurugan, R.; Chen, K.; Gheysens, O.; Rodriguez-Porcel, M.; Lutz, A.M.; Chen, I.Y.; Chen, X.; Gambhir, S.S. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology, 2008, 246, 508-518.
81. Willmann, J.K.; Lutz, A.M.; Paulmurugan, R.; Patel, M.R.; Chu, P.; Rosenberg, J.; Gambhir, S.S. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology, 2008, 248, 936-944.
82. Korpanty, G.; Carbon, J.G.; Grayburn, P.A.; Fleming, J.B.; Brekken, R.A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin. Cancer Res., 2007, 13, 323-330.
83. Palmowski, M.; Huppert, J.; Ladewig, G.; Hauff, P.; Reinhardt, M.; Mueller, M.M.; Woenne, E.C.; Jenne, J.W.; Maurer, M.; Kauffmann, G.W.; Semmler, W.; Kiessling, F. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol. Cancer Ther., 2008, 7, 101-109.
84. Palmowski, M.; Peschke, P.; Huppert, J.; Hauff, P.; Reinhardt, M.; Maurer, M.; Karger, C.P.; Scholz, M.; Semmler, W.; Huber, P.E.; Kiessling, F.M. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia., 2009, 11, 856-863.
85. Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 2003, 17, 545-580.
86. Weissleder, R.; Mahmood, U. Molecular imaging. Radiology, 2001, 219, 316-333.
87. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med., 2008, 49 (Suppl 2), 113S-128S.
88. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S.S.; Chen, X. Nearinfrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug. Chem., 2005, 16, 1433-1441.
89. Medintz, I.L.; Uyeda, H.T.; Goldman, E.R.; Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater., 2005, 4, 435-446.
90. Cai, W.; Shin, D.W.; Chen, K.; Gheysens, O.; Cao, Q.; Wang, S.X.; Gambhir, S.S.; Chen, X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano. Lett., 2006, 6, 669-676.
91. Cai, W.; Chen, K.; Li, Z.B.; Gambhir, S.S.; Chen, X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med., 2007, 48, 1862-1870.
92. Backer, M.V.; Levashova, Z.; Patel, V.; Jehning, B.T.; Claffey, K.; Blankenberg, F.G.; Backer, J.M. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat. Med., 2007, 13, 504-509.
93. Bremer, C.; Tung, C.H.; Weissleder, R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med., 2001, 7, 743-748.
94. Ntziachristos, V.; Tung, C.H.; Bremer, C.; Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med., 2002, 8, 757-760.
95. Hoffman, R.M.; Yang, M. Color-coded fluorescence imaging of tumor-host interactions. Nat. Protoc., 2006, 1, 928-935.
96. Yang, M.; Li, L.; Jiang, P.; Moossa, A.R.; Penman, S.; Hoffman, R.M. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 14259-14262.
97. Amoh, Y.; Li, L.; Tsuji, K.; Moossa, A.R.; Katsuoka, K.; Hoffman, R.M.; Bouvet, M. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine. J. Surg. Res., 2006, 132, 164-169.